| MeSH term | MeSH ID | Detail |
|---|---|---|
| Abnormalities, Multiple | D000015 | 13 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Acne Vulgaris | D000152 | 35 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Adrenal Insufficiency | D000309 | 3 associated lipids |
| Akinetic Mutism | D000405 | 1 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alopecia | D000505 | 14 associated lipids |
| Alopecia Areata | D000506 | 6 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| de Fijter JW et al. | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. | 2017 | Am. J. Transplant. | pmid:28027625 |
| Kabat-Koperska J et al. | Birth defects in juvenile Wistar rats after exposure to immunosuppressive drugs during pregnancy. | 2017 | Histol. Histopathol. | pmid:27097725 |
| Elens L and Haufroid V | Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22? | 2017 | Pharmacogenomics | pmid:29095105 |
| Li Y et al. | [Study on the Effect of Immunosuppressive Agent FK506 on Growth and Migration of Lung Cancer Cell]. | 2017 | Zhongguo Fei Ai Za Zhi | pmid:28738959 |
| Nakamura Y et al. | Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation. | 2017 | Intern. Med. | pmid:28502936 |
| Sanghavi K et al. | Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. | 2017 | Pharmacogenomics J. | pmid:26667830 |
| Heemann U and Viklicky O | Is trough level variability the new tool for identifying patients at risk for rejection after transplantation? | 2017 | Nephrol. Dial. Transplant. | pmid:28186537 |
| Størset E et al. | Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. | 2017 | Br J Clin Pharmacol | pmid:28374426 |
| Ericzon BG et al. | Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy. | 2017 | Clin Transplant | pmid:28295581 |
| Morita M et al. | The onset risk of carcinoma in patients continuing tacrolimus topical treatment for oral lichen planus: a case report. | 2017 | Odontology | pmid:27368962 |
| Shimizu S et al. | Reduction of FR900525 using an S-(2-aminoethyl) l-cysteine-resistant mutant. | 2017 | J. Biosci. Bioeng. | pmid:28185832 |
| Sakurai K et al. | Efficacy of combination therapy with tacrolimus and mizoribine for cyclophosphamide-resistant ANCA-associated glomerulonephritis. | 2017 | Int J Rheum Dis | pmid:28205382 |
| Chung BH et al. | Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Th17-Immune Responses in Kidney Transplant Recipients With Tacrolimus-Based Immunosuppression. | 2017 | Transplantation | pmid:28107277 |
| Wungwattana M and Savic M | Tacrolimus interaction with nafcillin resulting in significant decreases in tacrolimus concentrations: A case report. | 2017 | Transpl Infect Dis | pmid:28067989 |
| Ak K et al. | Tacrolimus-Eluting Suture Inhibits Neointimal Hyperplasia: An Experimental In Vivo Study in Rats. | 2017 | Eur J Vasc Endovasc Surg | pmid:28065442 |
| Ivulich S et al. | Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post-Lung Transplantation. | 2017 | Transplant. Proc. | pmid:29149976 |
| Gelens MACJ et al. | No evidence for progressive deterioration in stimulated insulin secretion in renal transplant recipients after 12years tacrolimus exposure. | 2017 | J. Diabetes Complicat. | pmid:28720321 |
| Tremblay S and Alloway RR | Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations. | 2017 | AAPS J | pmid:28717926 |
| Chen P et al. | Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. | 2017 | J Clin Pharm Ther | pmid:27885697 |
| Burbulla LF et al. | Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. | 2017 | Science | pmid:28882997 |